Os efeitos dos nutracêuticos no tratamento da doença hepática gordurosa não alcoólica: uma revisão integrativa

Ariclécio Cunha de Oliveira; Karla Katherine Gomes Viana; Ana Thaís Alves Lima; Sara Idelbrando da Silva Martinho; Danielly Ramalho de Oliveira

doi:10.33448/rsd-v9i8.5866

Autores

Ariclécio Cunha de Oliveira Universidade Estadual do Ceará https://orcid.org/0000-0002-9295-8157
Karla Katherine Gomes Viana Universidade Estadual do Ceará https://orcid.org/0000-0003-4874-962X
Ana Thaís Alves Lima Faculdade de Quixeramobim https://orcid.org/0000-0002-2939-9962
Sara Idelbrando da Silva Martinho Centro Universitário Estácio de Sá https://orcid.org/0000-0003-3104-2986
Danielly Ramalho de Oliveira Centro Universitário Estácio de Sá https://orcid.org/0000-0002-4215-5735

DOI:

https://doi.org/10.33448/rsd-v9i8.5866

Palavras-chave:

A doença hepática gordurosa não alcoólica (DHGNA) é caracterizada pelo acúmulo de gordura nos hepatócitos na ausência de ingestão alcoólica e é a mais comum das doenças crônicas do fígado no mundo. Os pilares do tratamento da DHGA são; estilo de vida sau

Resumo

A doença hepática gordurosa não alcoólica (DHGNA) é caracterizada pelo acúmulo de gordura nos hepatócitos na ausência de ingestão alcoólica e é a mais comum das doenças crônicas do fígado no mundo. Os pilares do tratamento da DHGA são: estilo de vida saudável, como modificações na dieta, prática de atividade física regular e perda de peso gradual. Este trabalho teve como objetivo realizar uma revisão integrativa sobre os efeitos dos nutracêuticos no tratamento da DHGNA. Para o levantamento bibliográfico, optou-se pela busca de artigos nas bases de dados PubMed (National Library of Medicine), LILACS (Literatura Latino-Americana em Ciências da Saúde) e SciELO (Scientific Eletronic Library Online), realizados com humanos e publicados nos últimos 5 anos, nos idiomas Português, Inglês e Espanhol. Aplicou-se a combinação dos seguintes descritores: “Doença Hepática Gordurosa não Alcoólica”, “Nutracêuticos” e “Dieta”. Os artigos selecionados apontam a relação do consumo dos nutracêuticos com a melhora de alguns marcadores relacionados à DHGNA, servindo como terapia alternativa no tratamento da DHGNA. Apesar dos efeitos relatados acerca do uso de nutracêuticos no tratamento da DHGNA, observa-se a necessidade de mais pesquisas a respeito do assunto abordado.

Referências

Aggarwal, B. (2010). Targeting Inflammation-Induced Obesity and Metabolic Diseases by Curcumin and Other Nutraceuticals. Annual Review of Nutrition, 30(1), 173-199.

Bacchi., et al. (2013). Both Resistance Training and Aerobic Training Reduce Hepatic Fat Content in Type 2 Diabetic Subjects With Nonalcoholic Fatty Liver Disease (The RAED2 Randomized Trial). Hepatology, 58(4), 1287-1295.

Bahadoran., et al. (2013). The association of dietary phytochemical index and cardiometabolic risk factors in adults: Tehran Lipid and Glucose Study. Journal of Human Nutrition and Dietetics, 23(1), 145-153.

Ben., et al. (2016). The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. British Journal of Clinical Pharmacology, 83(1), 88-95.

Bhatt., et al. (2012). Resveratrol Improves Glycemic Control in Type 2 Diabetic Obese Mice by Regulating Glucose Transporter Expression in Skeletal Muscle and Liver. Nutrition Research, 32(7), 537-541.

Bo., et al. (2013). Anti-Inflammatory and Antioxidant Effects of Resveratrol in Healthy Smokers A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial. Current Medicinal Chemistry, 20(10), 1323-1331.

Byrne., et al. (2015). NAFLD: A Multisystem Disease. Journal of Hepatology, 62(1), 47-64.

Capanni., et al. (2006). Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Alimentary Pharmacology and Therapeutics, 23(8), 1143-1151.

Charchay., et al. (2014). Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 12(12), 2092-2103.

Chang, L., Chiang, S. H., & Saltiel, A. R. (2004). Insulin signaling and the regulation of glucose transport. Molecular medicine (Cambridge, Mass.), 10(7-12), 65–71.

Charlton, M. (2004). Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clinical gastroenterology and hepatology: the official clinical practice journal of the American

Gastroenterological Association, 2(12), 1048–1058.

Chen, S., Zhao, X., Ran, L., Wan, J., Wang, X., Qin, Y., Shu, F., Gao, Y., Yuan, L., Zhang, Q., & Mi, M. (2015). Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 47(3), 226–232.

Choi, Y. J., Suh, H. R., Yoon, Y., Lee, K. J., Kim, D. G., Kim, S., & Lee, B. H. (2014). Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. Archives of pharmacal research, 37(9), 1169–1176.

Cicero, A. F., Morbini, M., & Borghi, C. (2015). Do we need 'new' omega-3 polyunsaturated fatty acids formulations?. Expert opinion on pharmacotherapy, 16(3), 285–288.

Cotrim, H. P., Parise, E. R., Figueiredo-Mendes, C., Galizzi-Filho, J., Porta, G., & Oliveira, C. P. (2016). Nonalcoholic Fatty Liver Disease Brazilian Society of Hepatology Consensus. Arquivos de gastroenterologia, 53(2), 118–122.

Couto, O. (2019 08th May). Doença hepática gordurosa não alcoólica. [Weblog]. Retrieved 01 November 2019, from: https://www.acoesunimedbh.com.br/sessoesclinicas/wordpress/wp-content /uploads/2019/05/Doenca-Hepatica-Gordusa-nAo-Alcoolica_Final-versao-29-05.pdf.

Day, C. P., & James, O. F. (1998).Steatohepatitis: a tale of two "hits"?. Gastroenterology, 114(4), 842–845.

Faghihzadeh, F., Adibi, P., & Hekmatdoost, A. (2015). The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled study. The British journal of nutrition, 114(5), 796–803.

Golabi, P., Bush, H., & Younossi, Z.M. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis, 21(4), 739-753.

Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016). Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annual review of pathology, 11, 451–496.

Heebøll, S., Kreuzfeldt, M., Hamilton-Dutoit, S., KjærPoulsen, M., Stødkilde-Jørgensen, H., Møller, H. J., Jessen, N., Thorsen, K., Kristina Hellberg, Y., Bønløkke Pedersen, S., & Grønbæk, H. (2016). Placebo-controlled, randomized clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scandinavian journal of gastroenterology, 51(4), 456–464.

Janczyk, W., Lebensztejn, D., Wierzbicka-Rucińska, A., Mazur, A., Neuhoff-Murawska, J., Matusik, P., & Socha, P. (2015). Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. The Journal of pediatrics, 166(6), 1358–63.e633.

Latruffe, N., Lançon, A., Frazzi, R., Aires, V., Delmas, D., Michaille, J. J., Djouadi, F., Bastin, J., & Cherkaoui-Malki, M. (2015).Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on inflammation. Annals of the New York Academy of Sciences, 1348(1), 97–106.

Li, L., Hai, J., Li, Z., Zhang, Y., Peng, H., Li, K., & Weng, X. (2014). Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association, 63, 166–173.

Li, Y. H., Yang, L. H., Sha, K. H., Liu, T. G., Zhang, L. G., & Liu, X. X. (2015). Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World journal of gastroenterology, 21(22), 7008–7013.

Liu, K., Zhou, R., Wang, B., & Mi, M. T. (2014). Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. The American journal of clinical nutrition, 99(6), 1510–1519.

Lomonaco, R., Sunny, N. E., Bril, F., & Cusi, K. (2013). Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs, 73(1), 1–14.

Martín-Domínguez, V., González-Casas, R., Mendoza-Jiménez-Ridruejo, J., García-Buey, L., & Moreno-Otero, R. (2013). Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease. Revista espanola de enfermidades digestivas: organo oficial de La Sociedad Espanola de Patologia Digestiva, 105(7), 409–420.

McKenney, J. M., & Sica, D. (2007). Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists, 64(6), 595–605.

Mendes, Karina Dal Sasso, Silveira, Renata Cristina de Campos Pereira, & Galvão, Cristina Maria. (2008). Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto - Enfermagem, 17(4), 758-764.

Mitchel, E. B., & Lavine, J. E. (2014). Review article: the management of pediatric nonalcoholic fatty liver disease. Alimentary pharmacology & therapeutics, 40(10), 1155–1170.

Nabavi, S. F., Nabavi, S. M., Abolhasani, F., Moghaddam, A. H., & Eslami, S. (2012). Cytoprotective effects of curcumin on sodium fluoride-induced intoxication in rat erythrocytes. Bulletin of environmental contamination and toxicology, 88(3), 486–490.

Nabavi, S. F., Moghaddam, A. H., Eslami, S., &Nabavi, S. M. (2012). Protective effects of curcumin against sodium fluoride-induced toxicity in rat kidneys. Biological trace element research, 145(3), 369–374.

Nanji, A. A., Jokelainen, K., Rahemtulla, A., Miao, L., Fogt, F., Matsumoto, H., Tahan, S. R., & Su, G. L. (1999). Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat. Hepatology (Baltimore, Md.), 30(4), 934–943.

Nogueira, M. A., Oliveira, C. P., Ferreira Alves, V. A., Stefano, J. T., Rodrigues, L. S., Torrinhas, R. S., Cogliati, B., Barbeiro, H., Carrilho, F. J., & Waitzberg, D. L. (2016). Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clinical nutrition (Edinburgh, Scotland), 35(3), 578–586.

Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Soflaei, S. S., Majeed, M., & Sahebkar, A. (2016). Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. Nutrition (Burbank, Los Angeles County, Calif.), 32(10), 1116–1122.

Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Simental-Mendía, L. E., Majeed, M., & Sahebkar, A. (2016). Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 82, 578–582.

Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendía, L. E., & Sahebkar, A. (2017). Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Drug research, 67(4), 244–251.

Panahi, Y., Khalili, N., Hosseini, M. S., Abbasinazari, M., & Sahebkar, A. (2014). Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complementary therapies in medicine, 22(5), 851–857.

Parker, H. M., Johnson, N. A., Burdon, C. A., Cohn, J. S., O'Connor, H. T., & George, J. (2012). Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of hepatology, 56(4), 944–951.

Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. (2013). High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes, 62(4), 1186–1195.

Rahmani, S., Asgary, S., Askari, G., Keshvari, M., Hatamipour, M., Feizi, A., & Sahebkar, A. (2016). Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Phytotherapy research: PTR, 30(9), 1540–1548.

Ramirez-Tortosa, M. C., Ramirez-Tortosa, C. L., Mesa, M. D., Granados, S., Gil, A., & Quiles, J. L. (2009). Curcumin ameliorates rabbits’ steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. Free radical biology & medicine, 47(7), 924–931.

Rivera-Espinoza, Y., & Muriel, P. (2009). Pharmacological actions of curcumin in liver diseases or damage. Liver international: official journal of the International Association for the Study of the Liver, 29(10), 1457–1466.

Rochlani, Y., Pothineni, N. V., Kovelamudi, S., & Mehta, J. L. (2017). Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Therapeutic advances in cardiovascular disease, 11(8), 215–225.

Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012). Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free radical biology & medicine, 52(1), 59–69.

Simopoulos A. P. (2008). The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Experimental biology and medicine (Maywood, N.J.), 233(6), 674–688.

Spadaro, L., Magliocco, O., Spampinato, D., Piro, S., Oliveri, C., Alagona, C., Papa, G., Rabuazzo, A. M., & Purrello, F. (2008). Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 40(3), 194–199.

Spahis, S., Alvarez, F., Ahmed, N., Dubois, J., Jalbout, R., Paganelli, M., Grzywacz, K., Delvin, E., Peretti, N., & Levy, E. (2018). Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. The Journal of nutritional biochemistry, 58, 28–36.

Tang, Y., Zheng, S., & Chen, A. (2009).Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology, 150(7), 3011–3020.

Timmers, S., & Schrauwn-hinderling, V. (2011). Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans. Cell Metabolism, 14(5), 612-622.

Van Herpen, N., & Schrauwn-hinderling, V. (2008). Lipid accumulation in non-adipose tissue and lipotoxicity. Physiology & Behavior, 94(2), 231-241.

Yang, L., Li, P., Fu, S., Calay, E. S., & Hotamisligil, G. S. (2010). Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metabolism, 11(6), 467–478.

Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B., Imai, S., Schechtman, K. B., Gu, C., Kunz, I., Rossi Fanelli, F., Patterson, B. W., & Klein, S. (2012). Resveratrol supplementation does not improve metabolic function in non-obese women with normal glucose tolerance. Cell Metabolism, 16(5), 658–664.

Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md.), 64(1), 73–84.

.

Os efeitos dos nutracêuticos no tratamento da doença hepática gordurosa não alcoólica: uma revisão integrativa

Autores

DOI:

Palavras-chave:

Resumo

Referências

Downloads

Publicado

Como Citar

Edição

Seção

Licença

JOURNAL METRICS

Idioma

Enviar Submissão